GSK plc
GSKToday
+1.51%
5 Days
+2.46%
1 Month
-0.68%
6 Months
-12.07%
Year to Date
+7.99%
1 Year
+40.93%
Recent
Analysis
GSK plc Stock (GSK) Closed Down by 3.17% on Jul 20: Facts Behind the Movement
• GSK stock faces downward pressure from ongoing Zantac litigation liabilities and regulatory uncertainty. • Heightened competition in vaccine markets and rising research costs impact investor sentiment. • Technical indicators, including Williams %R, signal potential selling pressure for the stock.
GSK plc Stock (GSK) Moved Down by 3.06% on Jul 17: Drivers Behind the Movement
• GSK shares face volatility due to ongoing Zantac litigation and potential settlement liabilities. • Industry pricing pressures and shifting institutional investment contribute to downward stock performance. • Uncertain clinical pipeline results and currency fluctuations impact the company's valuation and earnings.
GSK plc Stock (GSK) Moved Down by 5.22% on Apr 29: Drivers Behind the Movement
• GSK shares fell despite strong sales and reaffirmed guidance. • Earnings per share missed analyst estimates, driving negative market reaction. • Legal provisions and concerns about older medicines impacted investor confidence.
GSK plc Stock (GSK) Moved Up by 3.49% on Mar 25: Key Drivers Unveiled
• GSK's RSV vaccine gained expanded FDA approval for at-risk adults. • Investigational cancer drug received Orphan Drug Designation in Japan. • Analysts maintain a "buy" rating, citing easing uncertainties and growth guidance.
GSK plc Stock Opened Up by 3.02% on Feb 17: Drivers Behind the Movement
• European Commission approved GSK's Exdensur for two indications. • GSK began the fourth tranche of its £2 billion share buyback program. • GSK's stock shows buy signals based on technical indicators.
Trump Strikes Again: Sends Warning Letter to Eli Lilly and Others, Drug Pricing Back in the Spotlight
TradingKey - On Thursday Eastern Time, U.S. President Donald Trump renewed pressure on the pharmaceutical industry by sending formal letters to several major drugmakers
GSK plc's Score
Media Coverage
Analyst Rating
GSK plc Technical Analysis
Technical Indicators
Summary
Moving Average
Financial Indicators
Earnings
GSK plc Profile
Ownership
| Shareholders | Proportion |
|---|---|
| Dodge & Cox | 3.38% |
| Fidelity Management & Research Company LLC | 2.81% |
| Fisher Investments | 1.70% |
| PRIMECAP Management Company | 1.24% |
| Shareholder Types | Proportion |
|---|---|
| Investment Advisor | 9.06% |
| Investment Advisor/Hedge Fund | 8.17% |
| Research Firm | 1.01% |
| Hedge Fund | 0.92% |
Related Instruments
Popular Instruments
